{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:37:14Z","timestamp":1790289434744,"version":"4.1.0"},"reference-count":21,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Reports"],"abstract":"<jats:p>This paper assesses the preferred treatment patterns for retinopathy of prematurity (ROP) and examine trends in anti-vascular endothelial growth factor (VEGF) use for ROP. Methods: A retrospective survey consisting of 14 questions was distributed to paediatric ophthalmology interest groups internationally. Main outcome measures included treatment patterns, proportion of anti-VEGF use in different stages of ROP; and comparison of first-line treatments as well as repeat anti-VEGF treatments. Results: Fifty-four ophthalmologists from 11 different countries responded to the survey. The number of respondents per question, except one, ranged between 50\u201354. Per annum, there was an average number of 394 infants screened by each respondent. Anti-VEGF was the preferred treatment method for aggressive (A)-ROP (64.1%), Type 1 ROP in zone 1 (71.7%), and Type 1 ROP in posterior zone 2 (56.6%). The majority used laser as the first-line treatment of Type 1 ROP in anterior zone 2 (73.6%) and Type 1 ROP in zone 3 (79.2%). Laser was the preferred treatment modality utilised in infants requiring repeat treatment following anti-VEGF injection. The preferred anti-VEGF agent was bevacizumab administered at a dose of 0.625 mg. Conclusions: Anti-VEGF as first-line therapy has been increasing. Anti-VEGF appears to be the first-line treatment of choice for A-ROP, Type 1 ROP in zone 1 and posterior zone 2 and laser for Type 1 ROP in anterior zone 2 and zone 3.<\/jats:p>","DOI":"10.3390\/pediatric16030069","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T03:03:37Z","timestamp":1726196617000},"page":"816-822","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Preferred Treatment Patterns of Retinopathy of Prematurity: An International Survey"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2115-129X","authenticated-orcid":false,"given":"Amy T.","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Queensland Children\u2019s Hospital, South Brisbane 4101, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7026-8155","authenticated-orcid":false,"given":"Shuan","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Queensland Children\u2019s Hospital, South Brisbane 4101, Australia"},{"name":"Menzies Health Institute Queensland, Griffith University, Gold Coast 4215, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.ophtha.2021.05.031","article-title":"International Classification of Retinopathy of Prematurity, Third Edition","volume":"128","author":"Chiang","year":"2021","journal-title":"Ophthalmology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e2021053924","DOI":"10.1542\/peds.2021-053924","article-title":"Retinopathy of Prematurity: A Global Perspective and Recent Developments","volume":"150","author":"Sabri","year":"2022","journal-title":"Pediatrics"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4103\/sjopt.sjopt_18_22","article-title":"Pathophysiology of retinopathy of prematurity","volume":"36","author":"Strube","year":"2022","journal-title":"Saudi J. Ophthalmol."},{"key":"ref_4","first-page":"Cd009734","article-title":"Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity","volume":"8","author":"Sankar","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Cryotherapy for Retinopathy of Prematurity Cooperative Group (1988). Multicenter Trial of Cryotherapy for Retinopathy of Prematurity: Preliminary Results. Arch. Ophthalmol., 106, 471\u2013479.","DOI":"10.1001\/archopht.1988.01060130517027"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1001\/jamaophthalmol.2019.4488","article-title":"Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity","volume":"138","author":"Crouch","year":"2020","journal-title":"JAMA Ophthalmol."},{"key":"ref_7","first-page":"233","article-title":"Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial","volume":"102","author":"Good","year":"2004","journal-title":"Trans. Am. Ophthalmol. Soc."},{"key":"ref_8","first-page":"603","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"17","author":"Kennedy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): An open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1001\/jamapediatrics.2017.4838","article-title":"Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity: A Randomized Clinical Trial","volume":"172","author":"Stahl","year":"2018","journal-title":"JAMA Pediatr."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1001\/jama.2022.10564","article-title":"Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial","volume":"328","author":"Stahl","year":"2022","journal-title":"JAMA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2147\/PHMT.S391591","article-title":"Role of Anti-Vascular Endothelial Growth Factor (Anti-VEGF) in the Treatment of Retinopathy of Prematurity: A Narrative Review in the Context of Middle-Income Countries","volume":"14","author":"Dogra","year":"2023","journal-title":"Pediatr. Health Med. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/bjophthalmol-2015-307263","article-title":"Five years of treatment for retinopathy of prematurity in Sweden: Results from SWEDROP, a national quality register","volume":"100","author":"Gerd","year":"2016","journal-title":"Br. J. Ophthalmol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e314","DOI":"10.1111\/aos.15753","article-title":"Comparability of input parameters in the German Retina.net ROP registry and the EU-ROP registry\u2014An exemplary comparison between 2011 and 2021","volume":"102","author":"Winter","year":"2024","journal-title":"Acta Ophthalmol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"806","DOI":"10.18240\/ijo.2020.05.17","article-title":"Laser therapy versus intravitreal injection of anti-VEGF agents in monotherapy of ROP: A Meta-analysis","volume":"13","author":"Wang","year":"2020","journal-title":"Int. J. Ophthalmol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s10792-021-02188-z","article-title":"Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment","volume":"42","author":"Erol","year":"2022","journal-title":"Int. Ophthalmol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4103\/joco.joco_193_21","article-title":"Comparison of Clinical Outcomes of Intravitreal Bevacizumab Aflibercept in Type 1 Prethreshold Retinopathy of Prematurity in Posterior Zone II","volume":"34","author":"Milani","year":"2022","journal-title":"J. Curr. Ophthalmol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jaapos.2023.05.008","article-title":"Reactivation of retinopathy of prematurity six years after intravitreal injection of bevacizumab","volume":"27","author":"Yasin","year":"2023","journal-title":"J. Am. Assoc. Pediatr. Ophthalmol. Strabismus"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/ICU.0000000000000786","article-title":"Description and management of retinopathy of prematurity reactivation after intravitreal antivascular endothelial growth factor therapy","volume":"32","author":"Valikodath","year":"2021","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_20","first-page":"178","article-title":"Imaging in Retinopathy of Prematurity","volume":"8","author":"Valikodath","year":"2019","journal-title":"Asia Pac. J. Ophthalmol."},{"key":"ref_21","first-page":"145","article-title":"Anti-VEGF for ROP and Pediatric Retinal Diseases","volume":"7","author":"Wu","year":"2018","journal-title":"Asia Pac. J. Ophthalmol."}],"container-title":["Pediatric Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2036-7503\/16\/3\/69\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:55:12Z","timestamp":1760111712000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2036-7503\/16\/3\/69"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,13]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["pediatric16030069"],"URL":"https:\/\/doi.org\/10.3390\/pediatric16030069","relation":{},"ISSN":["2036-7503"],"issn-type":[{"value":"2036-7503","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,13]]}}}